An Intravascular Bioartificial Pancreas (iBAP)

? DESCRIPTION (provided by applicant): Approximately 3 million Americans and around 24 million people worldwide are affected by Type 1 Diabetes (T1D). Glucose monitoring followed by exogenous insulin injection, allogeneic whole organ pancreas transplantation, and allogeneic islet transplantation are the most common treatments for T1D. These treatments have achieved glycemic control for many patients but result in serious complications. A bioartificial pancreas is a promising treatment for T1D because it contains functional islets. Unfortunately previous attempts at BAP development have been severely limited by insufficient mass transfer within the islet chamber. The founders of Silicon Kidney have developed silicon nanopore membranes (SNM) to achieve high-efficiency blood ultrafiltration while selectively retaining specific solutes for the Bioartificial Kidney Project and this project's successes are directly transferrable to the iBAP. The ultra-high-hydraulic-permeable characteristic of the SNM will e